Xiaomai Zhou

557 total citations
7 papers, 469 citations indexed

About

Xiaomai Zhou is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Xiaomai Zhou has authored 7 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Xiaomai Zhou's work include HER2/EGFR in Cancer Research (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and Pregnancy and preeclampsia studies (1 paper). Xiaomai Zhou is often cited by papers focused on HER2/EGFR in Cancer Research (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and Pregnancy and preeclampsia studies (1 paper). Xiaomai Zhou collaborates with scholars based in China and United States. Xiaomai Zhou's co-authors include Yimao Liu, Thomas W. Chittenden, Gillian Payne, Robert J. Lutz, Thomas Chittenden, Lisa M. Garrett, Walter A. Blättler, Katherine M. Connors, Erin K. Maloney and Rajeeva Singh and has published in prestigious journals such as Journal of Biological Chemistry, Environmental Science & Technology and Cancer Research.

In The Last Decade

Xiaomai Zhou

7 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaomai Zhou China 4 353 160 117 110 40 7 469
Xinwei Yun China 11 345 1.0× 133 0.8× 99 0.8× 147 1.3× 32 0.8× 21 509
Maria Luisa Nicolosi Italy 14 319 0.9× 256 1.6× 184 1.6× 160 1.5× 41 1.0× 14 606
Susanne Lingelbach Germany 10 168 0.5× 128 0.8× 139 1.2× 57 0.5× 36 0.9× 13 348
Rosemary E. Teresi United States 7 335 0.9× 97 0.6× 61 0.5× 227 2.1× 38 0.9× 10 494
Stephen Hillerman United States 4 241 0.7× 132 0.8× 118 1.0× 105 1.0× 22 0.6× 5 427
Dingyuan Luo China 13 201 0.6× 81 0.5× 73 0.6× 140 1.3× 39 1.0× 22 354
I‐Hsiao Chung Taiwan 16 446 1.3× 82 0.5× 75 0.6× 373 3.4× 49 1.2× 18 644
Zbigniew Tański Poland 12 320 0.9× 118 0.7× 70 0.6× 156 1.4× 30 0.8× 14 482
Hitoshi Funatomi Japan 10 382 1.1× 132 0.8× 314 2.7× 131 1.2× 37 0.9× 25 640
Kati Servan Germany 6 224 0.6× 51 0.3× 119 1.0× 105 1.0× 27 0.7× 6 389

Countries citing papers authored by Xiaomai Zhou

Since Specialization
Citations

This map shows the geographic impact of Xiaomai Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaomai Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaomai Zhou more than expected).

Fields of papers citing papers by Xiaomai Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaomai Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaomai Zhou. The network helps show where Xiaomai Zhou may publish in the future.

Co-authorship network of co-authors of Xiaomai Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaomai Zhou. A scholar is included among the top collaborators of Xiaomai Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaomai Zhou. Xiaomai Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Guo, Huihui, Hongsheng Xie, Yuanyuan Huang, et al.. (2025). The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy. Frontiers in Pharmacology. 16. 1532104–1532104. 1 indexed citations
2.
Li, Keying, et al.. (2024). TDMPP activation of estrogen receptor 2a regulates smc2 and p53 signaling to interfere with liver development in zebrafish (Danio rerio). Journal of Hazardous Materials. 477. 135379–135379. 3 indexed citations
3.
Han, Yi, Keying Li, Peng Li, et al.. (2024). Genetic Evidence for Estrogenic Effects of Benzophenone-2 on Zebrafish Neurodevelopment and Its Signaling Mechanism. Environmental Science & Technology. 58(49). 21433–21449. 3 indexed citations
4.
Zhou, Xiaomai, Hongsheng Xie, Huihui Guo, et al.. (2015). Abstract 4532: Functional evaluation of novel Tubulysin analogs as payloads for antibody-drug conjugates. Cancer Research. 75(15_Supplement). 4532–4532. 1 indexed citations
5.
Maloney, Erin K., Lisa M. Garrett, Katherine M. Connors, et al.. (2003). An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.. PubMed. 63(16). 5073–83. 260 indexed citations
6.
Zhou, Xiaomai, Yimao Liu, Gillian Payne, Robert J. Lutz, & Thomas W. Chittenden. (2000). Growth Factors Inactivate the Cell Death Promoter BAD by Phosphorylation of Its BH3 Domain on Ser155. Journal of Biological Chemistry. 275(32). 25046–25051. 194 indexed citations
7.
Sahni, Malika, Xiaomai Zhou, Latifa Bakiri, et al.. (1996). Identification of a Novel 135-kDa Grb2-binding Protein in Osteoclasts. Journal of Biological Chemistry. 271(51). 33141–33147. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026